Addition of Vildagliptin to Insulin Improves Glycaemic Control in Type 2 Diabetes.
From: Endocrinology Department, Tulane University Health Sciences Center, 1430 Tulane Avenue, New Orleans, LA 70112, USA. vfonseca@tulane.edu
Diabetologia
- Publish Date: Jun 2007
- ISSN: 0012-186X
- Volume: 50
- Issue: 6
- Pages: 1148-55
- Medium: Print
- Language: English
- Citation (JAMA): Fonseca V, Schweizer A, Albrecht D, et al. Addition of Vildagliptin to Insulin Improves Glycaemic Control in Type 2 Diabetes.. Diabetologia Jun 2007;50:1148-55
Abstract
AIMS/HYPOTHESIS: Type 2 diabetes is difficult to manage in patients with a long history of disease requiring insulin therapy. Moreover, addition of most currently available oral antidiabetic agents increases the risk of hypoglycaemia. Vildagliptin is a dipeptidyl peptidase-IV inhibitor, which improves glycaemic control by increasing pancreatic beta cell responsiveness to glucose and suppressing inappropriate glucagon secretion. This study assessed the efficacy and tolerability of vildagliptin added to insulin therapy in patients with type 2 diabetes. MATERIALS AND METHODS: This was a multicentre, 24-week, double-blind, randomised, placebo-controlled, parallel-group study in patients with type 2 diabetes that was inadequately controlled (HbA(1c) = 7.5-11%) by insulin. Patients received vildagliptin (n = 144; 50 mg twice daily) or placebo (n = 152) while continuing insulin therapy. RESULTS: Baseline HbA(1c) averaged 8.4 +/- 0.1% in both groups. The adjusted mean change from baseline to endpoint (AMDelta) in HbA(1c) was -0.5 +/- 0.1% and -0.2 +/- 0.1% in patients receiving vildagliptin or placebo, respectively, with a significant between-treatment difference (p = 0.01). In patients aged >/=65 years, the AMDelta HbA(1c) was -0.7 +/- 0.1% in the vildagliptin group vs -0.1 +/- 0.1% in the placebo group (p < 0.001). The incidence of adverse events was similar in the vildagliptin (81.3%) and placebo (82.9%) groups. However, hypoglycaemic events were less common (p < 0.001) and less severe (p < 0.05) in patients receiving vildagliptin than in those receiving placebo. CONCLUSIONS/INTERPRETATION: Vildagliptin decreases HbA(1c) in patients whose type 2 diabetes is poorly controlled with high doses of insulin. Addition of vildagliptin to insulin therapy is also associated with reduced confirmed and severe hypoglycaemia. ClinicalTrials.gov ID no.: NCT 00099931.
Mesh Headings (Keywords): Adamantane, Aged, Blood Glucose, Body Mass Index, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Female, Hemoglobin A, Glycosylated, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Male, Middle Aged, Nitriles, Placebos, Pyrrolidines
Check for Full Text / PubMed Unique Identifier (PMID): 17387446
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.